1. Home
  2. ELTX vs ONCY Comparison

ELTX vs ONCY Comparison

Compare ELTX & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

HOLD

Current Price

$8.17

Market Cap

141.3M

Sector

Health Care

ML Signal

HOLD

Logo Oncolytics Biotech Inc.

ONCY

Oncolytics Biotech Inc.

HOLD

Current Price

$1.04

Market Cap

106.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELTX
ONCY
Founded
2011
1998
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Pharmaceuticals and Biotechnology
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
141.3M
106.1M
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
ELTX
ONCY
Price
$8.17
$1.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$13.00
$6.00
AVG Volume (30 Days)
108.0K
695.5K
Earning Date
11-13-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.60
$0.33
52 Week High
$12.62
$1.51

Technical Indicators

Market Signals
Indicator
ELTX
ONCY
Relative Strength Index (RSI) 44.56 52.56
Support Level $7.90 $0.92
Resistance Level $8.78 $1.04
Average True Range (ATR) 0.65 0.07
MACD 0.04 0.01
Stochastic Oscillator 34.67 94.70

Price Performance

Historical Comparison
ELTX
ONCY

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.

About ONCY Oncolytics Biotech Inc.

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.

Share on Social Networks: